Anti-VEGFA antibody [VG-1] (ab1316)
Key features and details
- Mouse monoclonal [VG-1] to VEGFA
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
- Isotype: IgG1
Overview
-
Product name
Anti-VEGFA antibody [VG-1]
See all VEGFA primary antibodies -
Description
Mouse monoclonal [VG-1] to VEGFA -
Host species
Mouse -
Specificity
Detects the 121, 165 and 189 VEGF isoforms in routinely fixed specimens.
This antibody fails to detect endogenous natural samples in WB.
-
Tested Applications & Species
Application Species IHC-P MouseRatHumanWB MouseHuman -
Immunogen
corresponding to VEGFA.
-
Positive control
- Purchase matching WB positive control:Recombinant Human VEGFA protein
- WB: Recombinant human and mouse VEGFA; IHC-P: Human cerebellum and heart, Rat cerebellum, Mouse mammary fat pad and placenta.
-
General notes
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Some batches contain 6.97% L-Arginine as a stabilizing agent. For lot-specific buffer information, please contact our Scientific Support team. -
Concentration information loading...
-
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
VG-1 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab1316 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
IHC-P |
Mouse
Rat
Human
|
WB |
Mouse
Human
|
All applications |
Rabbit
Dog
|
Application | Abreviews | Notes |
---|---|---|
WB | (12) |
Use a concentration of 5 - 10 µg/ml.
Please note in our hands this antibody is sensitive to blocking conditions. If you are seeing no bands on your western blot, we suggest using 3% milk for 1 hr at RT for blocking. For the primary antibody incubation step, we suggest 1 hr at RT rather than overnight at 4°C. We would also recommend incubating primary and secondary antibodies in TBST only. |
IHC-P | (17) |
Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
Notes |
---|
WB
Use a concentration of 5 - 10 µg/ml. Please note in our hands this antibody is sensitive to blocking conditions. If you are seeing no bands on your western blot, we suggest using 3% milk for 1 hr at RT for blocking. For the primary antibody incubation step, we suggest 1 hr at RT rather than overnight at 4°C. We would also recommend incubating primary and secondary antibodies in TBST only. |
IHC-P
Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. -
Tissue specificity
Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. -
Involvement in disease
Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. -
Sequence similarities
Belongs to the PDGF/VEGF growth factor family. -
Cellular localization
Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. - Information by UniProt
-
Database links
- Entrez Gene: 7422 Human
- Entrez Gene: 22339 Mouse
- Entrez Gene: 100008899 Rabbit
- Entrez Gene: 83785 Rat
- Omim: 192240 Human
- SwissProt: P15692 Human
- SwissProt: Q00731 Mouse
- SwissProt: P16612 Rat
see all -
Alternative names
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)
IHC image of VEGFA staining in normal Mouse Placenta formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)
IHC image of ab1316 staining VEGF in human cerebellum formalin fixed paraffin embedded tissue sections, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5μg/ml working concentration, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the secondary only control (shown on the inset).
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
All lanes : Anti-VEGFA antibody [VG-1] (ab1316)
Lane 1 : Recombinant Human VEGFA protein (His tag) (ab204773)
Lane 2 :Recombinant mouse VEGFA protein (Active) (ab185265)
Lysates/proteins at 0.1 µg per lane.
Secondary
All lanes : Mouse IgG secondary antibody at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 24, 45 kDa
Observed band size: 23 kDa why is the actual band size different from the predicted?
Exposure time: 10 secondsThis blot was produced using a 10% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% Milk before being incubated with ab1316 overnight at 4°C. Antibody binding was detected using an anti-mouse antibody conjugated to HRP, and visualised using ECL development solution.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)
IHC image of ab1316 staining VEGF in rat cerebellum formalin fixed paraffin embedded tissue sections, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5μg/ml working concentration, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the secondary only control (shown on the inset).
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)This image is courtesy of an anonymous Abreviewab1316 staining VEGF in Human MDA-MD-231 cells injected into the mouse mammary fat pad by Immunohistochemistry (IHC-P - formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde, permeabilized with Tween in PBS and blocked with 1.5% serum for 1 hour at 25°C; antigen retrieval was by heat mediation in citrate buffer. Tissue samples were incubated with primary antibody (1/200 in PBST +1% BSA) for 16 hours at 4°C. A biotin-conjugated Goat anti-mouse IgG polyclonal (1/200) was used as the secondary antibody. Tissue was counterstained with Hematoxylin (1/10) for 30 seconds at room temperature and rinsed with water.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGFA antibody [VG-1] (ab1316)IHC image of ab1316 staining in human heart formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab1316, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
References (193)
ab1316 has been referenced in 193 publications.
- Mao Y et al. Fibroblast growth factor-2/platelet-derived growth factor enhances atherosclerotic plaque stability. J Cell Mol Med 24:1128-1140 (2020). PubMed: 31755222
- Zhang T et al. NMR-based metabolomic analysis for the effects of Huiyang Shengji extract on rat diabetic skin ulcers. J Ethnopharmacol N/A:112978 (2020). PubMed: 32442586
- Zhang J et al. Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief. Theranostics 10:4885-4899 (2020). PubMed: 32308756
- Póvoa VCO et al. Wound healing action of nitric oxide-releasing self-expandable collagen sponge. J Tissue Eng Regen Med 14:807-818 (2020). PubMed: 32330363
- Xu J et al. HIF1a overexpression enhances diabetic wound closure in high glucose and low oxygen conditions by promoting adipose-derived stem cell paracrine function and survival. Stem Cell Res Ther 11:148 (2020). PubMed: 32248837